Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1136927 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL9391576 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL11873346 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL4357343 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL16397659 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL20550870 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL7522970 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL10910201 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL6267065 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL7514273 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 552 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2000433-A | — | — | None | — | — | JP | disclosed |
| US-20240228669-A9 | A CONJUGATE, COMPOSITION AND METHOD FOR NONCOVALENT ANTIBODY CATENATION THAT INCREASES ANTIGEN-BINDING AVIDITY OF AN ANTIBODY IN PROPORTION TO THE DENSITY OF A TARGET ANTIGEN | KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2024-07-11 | — | — | US | disclosed |
| WO-2024144372-A1 | RECOMBINANT FUSION PROTEIN HAVING MODIFIED CYSTEINE RESIDUE FOR ANTIGEN DELIVERY AND USES THEREOF | 주식회사 엘지화학 | 2024-07-04 | — | — | WO | disclosed |
| WO-2024123010-A1 | LUMINESCENT PLATFORM FOR DUAL MEASUREMENT OF HCV/MIR-122 ACTIVITY, AND USE OF DERIVED SUBSTANCE RIGOSERTIB FOR TREATMENT OF SOFOSBUVIR-RESISTANT HCV | 국립암센터 | 2024-06-13 | — | — | WO | disclosed |
| EP-4365197-A1 | HUMANIZED ANTIBODY SPECIFIC TO CD47 AND PHARMACEUTICAL COMPOSITION COMPRISING SAME FOR PREVENTING OR TREATING CD47-RELATED DISEASE | Innobation Bio Co., Ltd. (KR) | 2024-05-08 | — | — | EP | disclosed |
| US-20240132625-A1 | A CONJUGATE, COMPOSITION AND METHOD FOR NONCOVALENT ANTIBODY CATENATION THAT INCREASES ANTIGEN-BINDING AVIDITY OF AN ANTIBODY IN PROPORTION TO THE DENSITY OF A TARGET ANTIGEN | KOREA ADVANCED INST SCI & TECH (KR) | 2024-04-25 | — | — | US | disclosed |
| CN-117881698-A | Humanized antibody having specificity for CD47 and pharmaceutical composition for preventing or treating CD 47-associated disease comprising the same | 创新生物有限公司 | 2024-04-12 | — | — | CN | disclosed |
| CN-111601892-B | Method for producing protein | 花王株式会社 | 2024-03-19 | — | — | CN | disclosed |
| WO-2024025397-A1 | RECOMBINANT FUSION PROTEIN FOR ANTIGEN DELIVERY AND USES THEREOF | 주식회사 엘지화학 | 2024-02-01 | — | — | WO | disclosed |
| US-20240034790-A1 | ANTIBODY SPECIFIC FOR CD47 AND USES THEREOF | INNOBATION BIO., LTD. (KR) | 2024-02-01 | — | — | US | disclosed |
| EP-0293793-A2 | Polypeptide and production thereof | Takeda Chemical Industries, Ltd. (JP) | 1988-12-07 | — | — | EP | disclosed |
| EP-0288200-A1 | Spiramycin resistance-conferring cloning vectors | ELI LILLY AND COMPANY (US) | 1988-10-26 | — | — | EP | disclosed |
| EP-0277563-A1 | Polypeptide and production thereof | Takeda Chemical Industries, Ltd. (JP) | 1988-08-10 | — | — | EP | disclosed |
| EP-0251244-A2 | Polypeptide and production thereof | Takeda Chemical Industries, Ltd. (JP) | 1988-01-07 | — | — | EP | disclosed |
| EP-0238324-A1 | Novel plasmid shuttle vectors conferring spiramycin resistance in streptomyces | ELI LILLY AND COMPANY (US) | 1987-09-23 | — | — | EP | disclosed |
| EP-0237966-A2 | Human basic fibroblast growth factor | Takeda Chemical Industries, Ltd. (JP) | 1987-09-23 | — | — | EP | disclosed |
| EP-0237737-A2 | A composition specific for Neisseria gonorrhoea | ENZO BIOCHEM, INC. (US) | 1987-09-23 | — | — | EP | disclosed |
| EP-0213779-A2 | Ultrahigh copy number streptomycetes plasmids | ELI LILLY AND COMPANY (US) | 1987-03-11 | — | — | EP | disclosed |
| WO-1983003413-A1 | CREATION OF DNA SEQUENCES ENCODING MODIFIED PROINSULIN PRECURSORS | GENETICS INST (US) | 1983-10-13 | — | — | WO | disclosed |
| EP-0090433-A1 | Creation of DNA sequences encoding modified proinsulin precursors | Genetics Institute, Inc. (US) | 1983-10-05 | — | — | EP | disclosed |